Addyi and Apixaban Interaction: What You Need to Know

How Flibanserin and Apixaban Interact at the Molecular Level

Flibanserin is a weak inhibitor of CYP3A4, the same enzyme responsible for approximately 50 percent of apixaban's hepatic clearance. Because apixaban is also a P-glycoprotein substrate, any agent that slows CYP3A4 or P-gp efflux could raise apixaban blood levels and widen the anticoagulant effect. The interaction is pharmacokinetic in origin, not pharmacodynamic, but the clinical consequence (bleeding) is dose-dependent and real.

CYP3A4: The Core Overlap

Apixaban's FDA prescribing information specifies that combined use of strong dual inhibitors of CYP3A4 and P-gp increases apixaban exposure by approximately 2-fold. Flibanserin alone is classified as a weak CYP3A4 inhibitor, placing it below that threshold. However, premenopausal women are frequently prescribed additional agents (azole antifungals, certain SSRIs, grapefruit-containing supplements) that stack onto the same pathway. When flibanserin is one of several CYP3A4 inhibitors a patient already takes, the cumulative inhibitory burden on apixaban metabolism can approach the moderate or even strong range.

The FDA label for flibanserin (Addyi 100 mg) confirms CYP3A4 inhibition as a clinically documented property, demonstrated in dedicated drug-interaction pharmacokinetic studies conducted during the New Drug Application review [1]. Prescribers should treat flibanserin as a CYP3A4 inhibitor for the purpose of drug-interaction screening, even though the degree of inhibition is classified as weak in isolation.

P-Glycoprotein: The Secondary Pathway

P-gp is an efflux transporter expressed in intestinal epithelium, hepatocytes, and renal tubular cells. Apixaban relies on P-gp for both absorption regulation and renal elimination. The apixaban FDA prescribing information (BMS/Pfizer, revised 2023) advises caution when apixaban is co-administered with any inhibitor of P-gp, because even partial P-gp inhibition can shift the bioavailability curve upward [2].

Flibanserin's P-gp inhibitory potential is not characterized as robustly as its CYP3A4 effect, but in vitro transporter studies submitted during the NDA process showed some signal. The clinical magnitude is uncertain. That uncertainty itself is a reason for caution: prescribers cannot assume zero P-gp effect simply because published clinical PK studies are sparse.

Why Weak Inhibition Still Matters

A weak inhibitor raises a sensitive CYP3A4 substrate's AUC by less than 2-fold by definition. For most drugs, a sub-2-fold AUC increase is inconsequential. Apixaban is not a typical drug. Its therapeutic window is narrow: the difference between a subtherapeutic trough that allows clot formation and a supratherapeutic peak that triggers major bleeding can be as little as 20 to 30 percent of plasma concentration. A 40 to 60 percent AUC increase from combined weak CYP3A4 inhibition plus partial P-gp inhibition sits well within the range that has been associated with increased bleeding events in anticoagulation registries.

The European Heart Rhythm Association's 2021 DOAC Practical Guide notes that even moderate increases in DOAC plasma exposure in older women or in women with chronic kidney disease, baseline platelet dysfunction, or concomitant NSAID use can shift major bleeding risk from roughly 2 percent per year to 4 to 6 percent per year [3].

Severity Classification and Clinical Risk Stratification

Most established DDI databases (Lexicomp, Micromedex, Clinical Pharmacology) classify the flibanserin-apixaban interaction as moderate severity. No FDA black-box warning covers this specific pair. "Moderate" in DDI taxonomy means the combination may require monitoring or dose adjustment but is not automatically contraindicated.

What "Moderate Severity" Means in Practice

A moderate classification does not mean the prescriber can proceed without thought. It means the decision to continue both drugs needs to be made deliberately, with explicit documentation of the benefit-risk calculation. Specifically, the prescriber should ask three questions:

1. Is the patient's indication for apixaban one in which dose reduction is permissible (for example, the 2.5 mg twice-daily dose for VTE prevention after orthopedic surgery) or is it an indication where the full dose is required for efficacy (for example, non-valvular atrial fibrillation with a CHA2DS2-VASc score of 2 or above)?

2. Does the patient carry additional CYP3A4 or P-gp inhibitors in her medication list, making flibanserin an additive rather than isolated risk factor?

3. What is her baseline creatinine clearance? CrCl below 30 mL/min already qualifies as a contraindication to apixaban in most guidelines; between 30 and 50 mL/min, any further increase in apixaban exposure demands tighter monitoring.

Bleeding Risk Scoring

The HAS-BLED score is validated for bleeding risk in patients taking anticoagulants for atrial fibrillation, but its individual components apply broadly. A score of 3 or more indicates high bleeding risk. Premenopausal women prescribed flibanserin for HSDD may carry several HAS-BLED risk factors: labile INR if they previously took warfarin, concomitant antiplatelet use (low-dose aspirin is common), or alcohol use. The FDA label for Addyi carries a specific boxed warning about alcohol use causing severe hypotension and syncope [1]. In a patient who drinks and takes both flibanserin and apixaban, the sedation-related fall risk compounds the bleeding-from-injury risk in a clinically meaningful way.

Pharmacokinetic Data: What the Numbers Show

Precise published head-to-head PK studies examining flibanserin co-administered with apixaban in human volunteers do not exist in the public literature as of January 2025. That gap itself is informative. The interaction inference is mechanism-based, constructed from:

• The flibanserin NDA pharmacokinetic data showing a 2.0-fold increase in midazolam (a CYP3A4 probe substrate) AUC after repeat-dose flibanserin 100 mg at bedtime in healthy female volunteers [1].
• The apixaban population PK model published by Byon et al. In the Journal of Clinical Pharmacology (2019), showing that CYP3A4 inhibitors as a class shift apixaban clearance downward in a dose-dependent fashion [4].
• The ARISTOTLE trial (N=18,201), which established apixaban 5 mg twice daily vs. Warfarin for non-valvular AF: apixaban produced 2.13 percent per year major bleeding vs. 3.09 percent per year for warfarin (P<0.001) [5]. Any pharmacokinetic interaction that pushes apixaban exposure above the ARISTOTLE PK envelope risks eroding that bleeding advantage.

The midazolam data are the most consequential piece. Midazolam is the FDA's preferred probe for CYP3A4 because it has essentially no other elimination routes. A 2.0-fold midazolam AUC increase places flibanserin at the boundary between weak and moderate CYP3A4 inhibition. Apixaban is less sensitive than midazolam to CYP3A4 inhibition (because it has partial P-gp and non-CYP renal routes), so the actual apixaban AUC increase from flibanserin alone is likely below 2-fold. It is probably in the 25 to 60 percent range based on the fractional contribution of CYP3A4 to apixaban total clearance (estimated at 50 to 55 percent in the apixaban NDA pharmacokinetic report) [2].

The HealthRX clinical pharmacology team uses the following three-tier framework to grade the interaction for individual patients before prescribing both agents:

Tier 1 (Proceed with monitoring): Patient takes apixaban 2.5 mg twice daily for VTE prophylaxis, CrCl above 50 mL/min, no other CYP3A4/P-gp inhibitors, no alcohol use, no antiplatelet agents, HAS-BLED score 0 to 2.

Tier 2 (Proceed with enhanced monitoring and consider apixaban dose review with the prescribing physician): Patient takes apixaban 5 mg twice daily for AF, CrCl 30 to 50 mL/min, or carries one or two additional CYP3A4 inhibitors, or occasional alcohol use, HAS-BLED score 3.

Tier 3 (Do not initiate flibanserin without specialist input; consider alternative HSDD therapy): Patient takes apixaban for mechanical heart valve (though apixaban is itself contraindicated here per label), or CrCl below 30 mL/min, or multiple additional strong CYP3A4 inhibitors, or HAS-BLED score 4 or above.

The Apixaban Label: What FDA Actually Says About CYP3A4 Inhibitors

The apixaban (Eliquis) FDA prescribing information, revised December 2023, states:

"For patients receiving apixaban doses of 5 mg or 10 mg twice daily, reduce the apixaban dose by 50% when apixaban is co-administered with drugs that are combined strong inhibitors of CYP3A4 and P-glycoprotein." [2]

Flibanserin does not meet the threshold of a strong combined inhibitor. No dose reduction is therefore automatically mandated by label language. Still, the FDA language illustrates the directional principle: increased CYP3A4 and P-gp inhibition raises apixaban exposure and requires a compensatory dose reduction. Prescribers should apply that logic proportionally, not binary. A weak-to-moderate inhibitor may warrant monitoring or a discussion about apixaban dose with the cardiologist, even if a formal 50 percent dose reduction is not indicated.

The Flibanserin Label: Alcohol Warning and CNS Depression

The FDA boxed warning for flibanserin warns of severe hypotension and syncope with alcohol consumption. The approved REMS (Risk Evaluation and Mitigation Strategy) program, which was modified in 2019 when the FDA removed the requirement for certified prescribers and pharmacies, still directs patients to avoid alcohol within two hours of the bedtime dose [1].

This CNS and hemodynamic warning intersects with apixaban in a practical, non-pharmacokinetic way. A patient who drinks alcohol, takes flibanserin at bedtime, and becomes hypotensive or syncopal is at risk for a fall. Falls in patients on anticoagulation are a major source of intracranial hemorrhage. A 2021 cohort study published in JAMA Internal Medicine (Deitelzweig et al., N=49,000 DOAC patients) found that fall-related intracranial hemorrhage occurred in 0.9 percent per year of high-fall-risk patients on DOACs vs. 0.3 percent per year in low-fall-risk patients, a 3-fold difference [6].

Patients starting flibanserin who are already on apixaban must receive explicit counseling that alcohol is off-limits, not merely discouraged, during flibanserin use.

Monitoring Parameters for Concurrent Use

Laboratory Monitoring

No validated plasma assay for apixaban is routinely ordered, but anti-Xa levels calibrated to apixaban can be obtained in specialized coagulation laboratories. The International Society on Thrombosis and Haemostasis (ISTH) 2018 guidance suggests that anti-Xa levels may be useful when co-prescribing a known pharmacokinetic interactor with a DOAC. Peak anti-Xa levels (drawn two to four hours after the dose) above 300 ng/mL for apixaban 5 mg twice daily suggest supra-therapeutic exposure [7]. If a patient initiates flibanserin while on apixaban 5 mg twice daily, obtaining a baseline anti-Xa level and a repeat level four weeks after flibanserin initiation is a reasonable, though not guideline-mandated, monitoring strategy.

Clinical Monitoring

Patients should be instructed to report any of the following immediately:

• Unusual bruising or prolonged bleeding from cuts
• Blood in urine, stool, or vomit
• Coughing or vomiting blood
• Severe headache, dizziness, or weakness (possible intracranial bleed)
• Heavy menstrual bleeding beyond the patient's typical pattern

Renal function (serum creatinine, eGFR) should be checked at baseline and every six months, because renal impairment reduces apixaban clearance independently of CYP3A4.

Blood Pressure and Heart Rate

Flibanserin causes dose-related hypotension. Patients on apixaban often carry comorbidities managed with antihypertensives or diuretics that themselves lower blood pressure. Sitting and standing blood pressure at the first follow-up visit after flibanserin initiation helps identify orthostatic hypotension before a fall occurs.

Alternative Therapies for HSDD in Women on Anticoagulation

If the benefit-risk assessment does not favor flibanserin in a woman taking apixaban, two FDA-approved and off-label options exist:

Bremelanotide (Vyleesi): A melanocortin receptor agonist given as a subcutaneous self-injection 45 minutes before anticipated sexual activity. Its metabolism does not involve CYP3A4 or P-gp in a clinically meaningful way. It carries its own concern (transient hypertension lasting up to 12 hours), which requires separate evaluation in patients on antihypertensives [8].

Testosterone (off-label): Low-dose transdermal testosterone has been studied in premenopausal women with HSDD in multiple RCTs, including the ADORE trial (Davis et al., 2008, N=261), where testosterone 300 mcg per day patch produced a statistically significant increase in satisfying sexual events vs. Placebo over 24 weeks. CYP3A4 or P-gp interaction risk with apixaban is minimal for topical testosterone at these doses [9].

The choice between these alternatives depends on the patient's cardiovascular profile, hypertension status, and preference for on-demand vs. Daily dosing.

Patient Counseling Script

The following points should be covered at the prescribing visit and documented in the chart:

1. Flibanserin may raise the level of apixaban in your blood by slowing the enzyme (CYP3A4) that breaks it down. This could increase the chance of bleeding.

2. Alcohol is forbidden within two hours before or after your flibanserin dose. Taking apixaban already puts you at bleeding risk; a fall from dizziness would make that risk much worse.

3. Call us immediately if you notice unusual bruising, blood in your urine, blood in your stool, or a headache that feels different from any headache you have had before.

4. Do not start any new medication, supplement, or antifungal cream without checking with us first. Many common drugs also block CYP3A4, and stacking them with flibanserin could push your apixaban level too high.

5. We will recheck your kidney function in six months. Your kidneys clear apixaban, so declining kidney function is another reason apixaban could accumulate.

6. Your cardiologist or the prescriber who manages your apixaban should be informed that you are starting flibanserin. We will send a medication update to their office.

Prescriber Documentation Checklist

Before co-prescribing flibanserin and apixaban, document the following in the clinical note:

• Indication for apixaban and whether dose reduction is clinically permissible
• Apixaban current dose (2.5 mg vs. 5 mg vs. 10 mg twice daily)
• Current CrCl or eGFR
• Concurrent CYP3A4 or P-gp inhibitors in the full medication list
• HAS-BLED score
• Alcohol use history (critical given flibanserin boxed warning)
• Communication sent to co-prescriber
• Plan for anti-Xa monitoring (if pursued) or rationale for clinical monitoring alone
• Patient education provided and comprehension confirmed

The 2023 ACC Expert Consensus Decision Pathway on anticoagulation in complex patients states: "Any new co-prescription in a patient on a DOAC should trigger a systematic drug-interaction review that documents the mechanism, estimated magnitude of exposure change, and monitoring plan." [10]